Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 24, 2006
April 21, 2020
b6150333-b5b8-4dc4-96ca-a0540463e9a1
Related Documents
Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997
Guidance DocumentFebruary 16, 2006Center for Drug Evaluation and Research
Nonclinical Safety Evaluation of Pediatric Drug Products
Guidance DocumentFebruary 15, 2006Center for Drug Evaluation and Research
Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format: Guidance for Industry
Guidance DocumentJanuary 24, 2006Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.